Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease.
Montreal cognitive assessment
N-terminal pro-B-type natriuretic peptide
high-sensitivity troponin I
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
17
02
2020
revised:
24
04
2020
accepted:
12
05
2020
pubmed:
20
6
2020
medline:
28
4
2021
entrez:
20
6
2020
Statut:
ppublish
Résumé
We assessed if cardiac blood markers are associated with motor and cognitive function in patients with Parkinson's disease (PD). High-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were evaluated in 285 PD patients. Furthermore, N-terminal pro-B-type natriuretic peptide levels were analyzed in 570 age, sex and cardiovascular risk factor matched healthy controls. Motor (UPDRS, Hoehn &Yahr) and cognitive function (Montreal Cognitive Assessemtn) were assessed at baseline in all 285 patients and after 1 year in 101 patients. N-terminal pro-B-type natriuretic peptide were significantly increased in 285 PD patients compared with 570 matched healthy controls. In PD patients, increased high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide levels were associated with worse motor function at baseline and also with motor decline after 1 year. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin I were inversely associated with cognitive function at baseline only in unadjusted models. Subclinical cardiac microdamage is associated with motor severity in PD patients. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
We assessed if cardiac blood markers are associated with motor and cognitive function in patients with Parkinson's disease (PD).
METHODS
High-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were evaluated in 285 PD patients. Furthermore, N-terminal pro-B-type natriuretic peptide levels were analyzed in 570 age, sex and cardiovascular risk factor matched healthy controls. Motor (UPDRS, Hoehn &Yahr) and cognitive function (Montreal Cognitive Assessemtn) were assessed at baseline in all 285 patients and after 1 year in 101 patients.
RESULTS
N-terminal pro-B-type natriuretic peptide were significantly increased in 285 PD patients compared with 570 matched healthy controls. In PD patients, increased high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide levels were associated with worse motor function at baseline and also with motor decline after 1 year. N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin I were inversely associated with cognitive function at baseline only in unadjusted models.
CONCLUSIONS
Subclinical cardiac microdamage is associated with motor severity in PD patients. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Substances chimiques
Biomarkers
0
Peptide Fragments
0
Natriuretic Peptide, Brain
114471-18-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1863-1868Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Références
Giannoccaro MP, La Morgia C, Rizzo G, Carelli V. Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson's disease. Mov Disord 2017;32(3):346-363.
Lang AE, Espay AJ. Disease modification in Parkinson's disease: current approaches, challenges, and future considerations. Mov Disord 2018;33(5):660-677.
Murphy E, Ardehali H, Balaban RS, et al. Mitochondrial function, biology, and role in disease: a scientific statement from the American Heart Association. Circ Res 2016;118(12):1960-1991.
Piqueras-Flores J, Lopez-Garcia A, Moreno-Reig A, et al. Structural and functional alterations of the heart in Parkinson's disease. Neurol Res 2018;40(1):53-61.
Zesiewicz TA, Strom JA, Borenstein AR, et al. Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey. Parkinsonism Relat Disord 2004;10(7):417-420.
Watanabe M, Takeda T, Nakamagoe K, Tamaoka A. Sequential imaging analysis using MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve in Parkinson's disease. Eur J Neurol 2011;18(7):1010-1013.
Kummer BR, Diaz I, Wu X, et al. Associations between cerebrovascular risk factors and Parkinson disease. Ann Neurol 2019;86(4):572-581.
Malek N, Lawton MA, Swallow DM, et al. Vascular disease and vascular risk factors in relation to motor features and cognition in early Parkinson's disease. Mov Disord 2016;31(10):1518-1526.
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol 2016;15(12):1257-1272.
Billia F, Hauck L, Grothe D, et al. Parkinson-susceptibility gene DJ-1/PARK7 protects the murine heart from oxidative damage in vivo. Proc Natl Acad Sci U S A 2013;110(15):6085-6090.
Billia F, Hauck L, Konecny F, Rao V, Shen J, Mak TW. PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function. Proc Natl Acad Sci U S A 2011;108(23):9572-9577.
Bhandari P, Song M, Chen Y, Burelle Y, Dorn GW 2nd. Mitochondrial contagion induced by Parkin deficiency in Drosophila hearts and its containment by suppressing mitofusin. Circ Res 2014;114(2):257-265.
Neumann JT, Twerenbold R, Ojeda F, et al. Application of high-sensitivity troponin in suspected myocardial infarction. N Engl J Med 2019;380(26):2529-2540.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27):2129-2200.
Mollenhauer B, Zimmermann J, Sixel-Doring F, et al. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa). Mov Disord 2019;34(1):67-77.
Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014;29(8):1010-1018.
Terman A, Kurz T, Navratil M, Arriaga EA, Brunk UT. Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging. Antioxid Redox Signal 2010;12(4):503-535.
Bertens AS, Sabayan B, de Craen AJM, Van der Mast RC, Gussekloo J. High sensitivity cardiac troponin T and cognitive function in the oldest old: the Leiden 85-Plus Study. J Alzheimers Dis 2017;60(1):235-242.
Mirza SS, de Bruijn RF, Koudstaal PJ, et al. The N-terminal pro B-type natriuretic peptide, and risk of dementia and cognitive decline: a 10-year follow-up study in the general population. J Neurol Neurosurg Psychiatry 2016;87(4):356-362.
Schneider AL, Rawlings AM, Sharrett AR, et al. High-sensitivity cardiac troponin T and cognitive function and dementia risk: the atherosclerosis risk in communities study. Eur Heart J 2014;35(27):1817-1824.
Tynkkynen J, Hernesniemi JA, Laatikainen T, et al. High-sensitivity cardiac troponin I and NT-proBNP as predictors of incident dementia and Alzheimer's disease: the FINRISK Study. J Neurol 2017;264(3):503-511.
Sabayan B, van Buchem MA, de Craen AJ, et al. N-terminal pro-brain natriuretic peptide and abnormal brain aging: the AGES-Reykjavik Study. Neurology 2015;85(9):813-820.
MGJ, Henry RMA, Brunner-La Rocca HP, et al. Cross-sectional associations between cardiac biomarkers, cognitive performance, and structural brain changes are modified by age. Arterioscler Thromb Vasc Biol 2018;38(8):1948-1958.
Kerola T, Nieminen T, Hartikainen S, Sulkava R, Vuolteenaho O, Kettunen R. B-type natriuretic peptide as a predictor of declining cognitive function and dementia-a cohort study of an elderly general population with a 5-year follow-up. Ann Med 2010;42(3):207-215.
Wijsman LW, Sabayan B, van Vliet P, et al. N-terminal pro-brain natriuretic peptide and cognitive decline in older adults at high cardiovascular risk. Ann Neurol 2014;76(2):213-222.